{"timestamp": "2025-05-26 11:13:04.380495", "question": "Clinical Scenario:\nA 56-year-old man with end-stage liver disease secondary to NASH cirrhosis is undergoing orthotopic liver transplantation. Thirty minutes after reperfusion, the surgical team notes ongoing oozing from the anastomotic site. ROTEM is performed and shows:\n\t\u2022\tEXTEM A10: 35 mm \n\t\u2022\tEXTEM CFT: 145 s \n\t\u2022\tFIBTEM A10: 7 mm \n\t\u2022\tEXTEM CT: 80 s\n\t\u2022\tML EXTEM: 5%\n\nClinical Question:\nWhat is the next best step in therapy? Give a precise, single best answer.\n", "answer": "This ROTEM result suggests a problem with fibrinogen.  The next best step is to administer fibrinogen concentrate.", "model": "gemini-1.5-pro"}
{"timestamp": "2025-05-26 11:19:31.281792", "session_id": "8072acb6", "query_metadata": {"question": "#1\nClinical Scenario:\nA 56-year-old man with end-stage liver disease secondary to NASH cirrhosis is undergoing orthotopic liver transplantation. Thirty minutes after reperfusion, the surgical team notes ongoing oozing from the anastomotic site. ROTEM is performed and shows:\n\t\u2022\tEXTEM A10: 35 mm \n\t\u2022\tEXTEM CFT: 145 s \n\t\u2022\tFIBTEM A10: 7 mm \n\t\u2022\tEXTEM CT: 80 s\n\t\u2022\tML EXTEM: 5%\n\nClinical Question:\nWhat is the next best step in therapy? Give a precise, single best answer.\n", "question_length": 467, "chat_history_length": 1, "retrieval_k": 5, "chunks_retrieved": 5, "model_used": "gemini-1.5-pro"}, "response_metadata": {"answer": "The ROTEM results suggest a problem with fibrinogen.  The low FIBTEM A10 (7 mm) indicates reduced clot strength due to low fibrinogen.  Therefore, the next best step is to administer fibrinogen concentrate.", "answer_length": 206, "response_time_seconds": 2.950592}, "sources": [{"chunk_id": "chunk_0", "source_document": "curry_et_al-2018-british_journal_of_haematology.pdf", "content": "|-----------------------------|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------", "content_length": 500, "similarity_score": null, "full_metadata": {"source": "curry_et_al-2018-british_journal_of_haematology.pdf"}, "retrieval_rank": 1}, {"chunk_id": "chunk_1", "source_document": "curry_et_al-2018-british_journal_of_haematology.pdf", "content": "Johansson, P.I. (2012) Coagulation monitoring of the bleeding traumatized patient. Current Opinion in Anesthesiology , 25 , 235 -241.\n\nJohansson, P.I. &amp; Stensballe, J. (2009) Effect of haemostatic control resuscitation on mortality in massively bleeding patients: a before and after study. Vox Sanguinis , 96 , 111 -118.\n\nJohansson, P.I., Stensballe, J., Oliveri, R., Wade, C.E., Ostrowski, S.R. &amp; Holcomb, J.B. (2014) How I treat patients with massive hemorrhage. Blood , 124 , 3052 -3058.\n\n", "content_length": 500, "similarity_score": null, "full_metadata": {"source": "curry_et_al-2018-british_journal_of_haematology.pdf"}, "retrieval_rank": 2}, {"chunk_id": "chunk_2", "source_document": "curry_et_al-2018-british_journal_of_haematology.pdf", "content": "## Review process\n\nThe document will be reviewed regularly by the relevant Task Force and the literature search will be re-run every 3 years to search for any RCT or other high-quality data that is either new or that may have been missed. The document will be archived and removed from the BSH current guidelines website if it becomes obsolete. If new recommendations are made an addendum will be published on the BSH guidelines website (www.b-s-h.org.uk).\n\n## Disclaimer\n\nWhile the advice and inform", "content_length": 500, "similarity_score": null, "full_metadata": {"source": "curry_et_al-2018-british_journal_of_haematology.pdf"}, "retrieval_rank": 3}, {"chunk_id": "chunk_3", "source_document": "curry_et_al-2018-british_journal_of_haematology.pdf", "content": "|                 | TEG 5000 (cup and pin method)         | TEG 6s (cartridge method)   | What the trace looks at:                                                                                                                                                                                                                                                                                |\n|-----------------|---------------------------------------|-----------------------------|-----------------------", "content_length": 500, "similarity_score": null, "full_metadata": {"source": "curry_et_al-2018-british_journal_of_haematology.pdf"}, "retrieval_rank": 4}, {"chunk_id": "chunk_4", "source_document": "curry_et_al-2018-british_journal_of_haematology.pdf", "content": "|                 | Kaolin, TF                            | Kaolin, TF,                 |                                                                                                                                                                                                                                                                                                         |\n|                 | FF:                                   | CFF:                        | Platelet inhibitor add", "content_length": 500, "similarity_score": null, "full_metadata": {"source": "curry_et_al-2018-british_journal_of_haematology.pdf"}, "retrieval_rank": 5}], "pinecone_metadata": {"namespace": "thera-rag", "index_name": "medical-rag-index", "embedding_model": "models/embedding-001"}}
{"timestamp": "2025-05-26 11:37:06.540574", "session_id": "883b99b3", "query_metadata": {"question": "#1\nClinical Scenario:\nA 56-year-old man with end-stage liver disease secondary to NASH cirrhosis is undergoing orthotopic liver transplantation. Thirty minutes after reperfusion, the surgical team notes ongoing oozing from the anastomotic site. ROTEM is performed and shows:\n\t\u2022\tEXTEM A10: 35 mm \n\t\u2022\tEXTEM CFT: 145 s \n\t\u2022\tFIBTEM A10: 7 mm \n\t\u2022\tEXTEM CT: 80 s\n\t\u2022\tML EXTEM: 5%\n\nClinical Question:\nWhat is the next best step in therapy? Give a precise, single best answer.\n", "question_length": 467, "chat_history_length": 1, "retrieval_k": 5, "chunks_retrieved": 5, "model_used": "gemini-1.5-pro"}, "response_metadata": {"answer": "The ROTEM results suggest a fibrinogen deficiency.  Therefore, the next best step in therapy is fibrinogen concentrate administration.", "answer_length": 134, "response_time_seconds": 3.135457}, "sources": [{"chunk_id": "chunk_0", "source_document": "curry_et_al-2018-british_journal_of_haematology.pdf", "content": "|-----------------------------|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------", "content_length": 500, "similarity_score": null, "full_metadata": {"source": "curry_et_al-2018-british_journal_of_haematology.pdf"}, "retrieval_rank": 1}, {"chunk_id": "chunk_1", "source_document": "curry_et_al-2018-british_journal_of_haematology.pdf", "content": "Johansson, P.I. (2012) Coagulation monitoring of the bleeding traumatized patient. Current Opinion in Anesthesiology , 25 , 235 -241.\n\nJohansson, P.I. &amp; Stensballe, J. (2009) Effect of haemostatic control resuscitation on mortality in massively bleeding patients: a before and after study. Vox Sanguinis , 96 , 111 -118.\n\nJohansson, P.I., Stensballe, J., Oliveri, R., Wade, C.E., Ostrowski, S.R. &amp; Holcomb, J.B. (2014) How I treat patients with massive hemorrhage. Blood , 124 , 3052 -3058.\n\n", "content_length": 500, "similarity_score": null, "full_metadata": {"source": "curry_et_al-2018-british_journal_of_haematology.pdf"}, "retrieval_rank": 2}, {"chunk_id": "chunk_2", "source_document": "curry_et_al-2018-british_journal_of_haematology.pdf", "content": "The remaining members of the writing group (SP, DK, HM) have no conflicts of interest to declare.\n## Review process\n\nThe document will be reviewed regularly by the relevant Task Force and the literature search will be re-run every 3 years to search for any RCT or other high-quality data that is either new or that may have been missed. The document will be archived and removed from the BSH current guidelines website if it becomes obsolete. If new recommendations are made an addendum will be publi", "content_length": 500, "similarity_score": null, "full_metadata": {"chunk_id": "chunk_022", "chunk_index": 27.0, "chunk_size": 1085.0, "chunk_strategy": "smart_semantic_with_overlap", "chunking_method": "section_based", "content_hash": "3a236a539bb1", "is_sub_chunk": false, "overlap_size": 300.0, "processing_timestamp": "1747760241.39581", "section_title": "Review process", "source": "curry_et_al-2018-british_journal_of_haematology.pdf", "source_file": "curry_et_al-2018-british_journal_of_haematology.json", "starts_with": "The remaining members of the writing group (SP, DK, HM) have no conflicts of interest to declare. ##", "word_count": 176.0}, "retrieval_rank": 3}, {"chunk_id": "chunk_3", "source_document": "curry_et_al-2018-british_journal_of_haematology.pdf", "content": "## Review process\n\nThe document will be reviewed regularly by the relevant Task Force and the literature search will be re-run every 3 years to search for any RCT or other high-quality data that is either new or that may have been missed. The document will be archived and removed from the BSH current guidelines website if it becomes obsolete. If new recommendations are made an addendum will be published on the BSH guidelines website (www.b-s-h.org.uk).\n\n## Disclaimer\n\nWhile the advice and inform", "content_length": 500, "similarity_score": null, "full_metadata": {"source": "curry_et_al-2018-british_journal_of_haematology.pdf"}, "retrieval_rank": 4}, {"chunk_id": "chunk_4", "source_document": "curry_et_al-2018-british_journal_of_haematology.pdf", "content": "|                 | FF:                                   | CFF:                        | Platelet inhibitor added: contribution of fibrinogen to clot remains.                                                                                                                                                                                                                                   |\n|                 | TF, Reopro                            |                             | When trace is compared", "content_length": 500, "similarity_score": null, "full_metadata": {"chunk_id": "chunk_004.3", "chunk_index": 5.0, "chunk_size": 14701.0, "chunk_strategy": "smart_semantic_with_overlap", "chunking_method": "hybrid_section_recursive", "content_hash": "d7b3e2231cdd", "is_sub_chunk": true, "overlap_size": 300.0, "parent_chunk": "chunk_004", "processing_timestamp": "1747760241.39581", "section_title": "Machine methodology, quality assurance and test accuracy", "source": "curry_et_al-2018-british_journal_of_haematology.pdf", "source_file": "curry_et_al-2018-british_journal_of_haematology.json", "starts_with": "The Association of Anaesthetists of Great Britain and Ireland endorsed the document. ## Machine meth", "word_count": 1399.0}, "retrieval_rank": 5}], "pinecone_metadata": {"namespace": "thera-rag", "index_name": "medical-rag-index", "embedding_model": "models/embedding-001"}}
{"timestamp": "2025-05-26 11:39:40.317717", "session_id": "883b99b3", "query_metadata": {"question": "#1 Clinical Scenario: A 56-year-old man with end-stage liver disease secondary to NASH cirrhosis is undergoing orthotopic liver transplantation. Thirty minutes after reperfusion, the surgical team notes ongoing oozing from the anastomotic site. ROTEM is performed and shows: \u2022 EXTEM A10: 35 mm \u2022 EXTEM CFT: 145 s \u2022 FIBTEM A10: 7 mm \u2022 EXTEM CT: 80 s \u2022 ML EXTEM: 5%\n\nClinical Question: What is the next best step in therapy? Give a precise, single best answer.", "question_length": 458, "chat_history_length": 1, "retrieval_k": 5, "chunks_retrieved": 5, "model_used": "gemini-1.5-pro"}, "response_metadata": {"answer": "Based on the provided ROTEM values, the patient shows signs of fibrinogen deficiency (low FIBTEM A10).  Therefore, the next best step is to administer fibrinogen concentrate.", "answer_length": 174, "response_time_seconds": 3.222315}, "sources": [{"chunk_id": "chunk_0", "source_document": "curry_et_al-2018-british_journal_of_haematology.pdf", "content": "|-----------------------------|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------", "content_length": 500, "similarity_score": null, "full_metadata": {"source": "curry_et_al-2018-british_journal_of_haematology.pdf"}, "retrieval_rank": 1}, {"chunk_id": "chunk_1", "source_document": "curry_et_al-2018-british_journal_of_haematology.pdf", "content": "Johansson, P.I. (2012) Coagulation monitoring of the bleeding traumatized patient. Current Opinion in Anesthesiology , 25 , 235 -241.\n\nJohansson, P.I. &amp; Stensballe, J. (2009) Effect of haemostatic control resuscitation on mortality in massively bleeding patients: a before and after study. Vox Sanguinis , 96 , 111 -118.\n\nJohansson, P.I., Stensballe, J., Oliveri, R., Wade, C.E., Ostrowski, S.R. &amp; Holcomb, J.B. (2014) How I treat patients with massive hemorrhage. Blood , 124 , 3052 -3058.\n\n", "content_length": 500, "similarity_score": null, "full_metadata": {"source": "curry_et_al-2018-british_journal_of_haematology.pdf"}, "retrieval_rank": 2}, {"chunk_id": "chunk_2", "source_document": "curry_et_al-2018-british_journal_of_haematology.pdf", "content": "The remaining members of the writing group (SP, DK, HM) have no conflicts of interest to declare.\n## Review process\n\nThe document will be reviewed regularly by the relevant Task Force and the literature search will be re-run every 3 years to search for any RCT or other high-quality data that is either new or that may have been missed. The document will be archived and removed from the BSH current guidelines website if it becomes obsolete. If new recommendations are made an addendum will be publi", "content_length": 500, "similarity_score": null, "full_metadata": {"chunk_id": "chunk_022", "chunk_index": 27.0, "chunk_size": 1085.0, "chunk_strategy": "smart_semantic_with_overlap", "chunking_method": "section_based", "content_hash": "3a236a539bb1", "is_sub_chunk": false, "overlap_size": 300.0, "processing_timestamp": "1747760241.39581", "section_title": "Review process", "source": "curry_et_al-2018-british_journal_of_haematology.pdf", "source_file": "curry_et_al-2018-british_journal_of_haematology.json", "starts_with": "The remaining members of the writing group (SP, DK, HM) have no conflicts of interest to declare. ##", "word_count": 176.0}, "retrieval_rank": 3}, {"chunk_id": "chunk_3", "source_document": "curry_et_al-2018-british_journal_of_haematology.pdf", "content": "## Review process\n\nThe document will be reviewed regularly by the relevant Task Force and the literature search will be re-run every 3 years to search for any RCT or other high-quality data that is either new or that may have been missed. The document will be archived and removed from the BSH current guidelines website if it becomes obsolete. If new recommendations are made an addendum will be published on the BSH guidelines website (www.b-s-h.org.uk).\n\n## Disclaimer\n\nWhile the advice and inform", "content_length": 500, "similarity_score": null, "full_metadata": {"source": "curry_et_al-2018-british_journal_of_haematology.pdf"}, "retrieval_rank": 4}, {"chunk_id": "chunk_4", "source_document": "curry_et_al-2018-british_journal_of_haematology.pdf", "content": "|                 | FF:                                   | CFF:                        | Platelet inhibitor added: contribution of fibrinogen to clot remains.                                                                                                                                                                                                                                   |\n|                 | TF, Reopro                            |                             | When trace is compared", "content_length": 500, "similarity_score": null, "full_metadata": {"chunk_id": "chunk_004.3", "chunk_index": 5.0, "chunk_size": 14701.0, "chunk_strategy": "smart_semantic_with_overlap", "chunking_method": "hybrid_section_recursive", "content_hash": "d7b3e2231cdd", "is_sub_chunk": true, "overlap_size": 300.0, "parent_chunk": "chunk_004", "processing_timestamp": "1747760241.39581", "section_title": "Machine methodology, quality assurance and test accuracy", "source": "curry_et_al-2018-british_journal_of_haematology.pdf", "source_file": "curry_et_al-2018-british_journal_of_haematology.json", "starts_with": "The Association of Anaesthetists of Great Britain and Ireland endorsed the document. ## Machine meth", "word_count": 1399.0}, "retrieval_rank": 5}], "pinecone_metadata": {"namespace": "thera-rag", "index_name": "medical-rag-index", "embedding_model": "models/embedding-001"}}
{"timestamp": "2025-05-26 11:48:59.271972", "session_id": "883b99b3", "query": "#1\nClinical Scenario:\nA 56-year-old man with end-stage liver disease secondary to NASH cirrhosis is undergoing orthotopic liver transplantation. Thirty minutes after reperfusion, the surgical team notes ongoing oozing from the anastomotic site. ROTEM is performed and shows:\n\t\u2022\tEXTEM A10: 35 mm \n\t\u2022\tEXTEM CFT: 145 s \n\t\u2022\tFIBTEM A10: 7 mm \n\t\u2022\tEXTEM CT: 80 s\n\t\u2022\tML EXTEM: 5%\n\nClinical Question:\nWhat is the next best step in therapy? Give a precise, single best answer.\n", "answer_length": 122, "response_time_seconds": 2.622297}
{"timestamp": "2025-05-26 12:08:31.880253", "session_id": "883b99b3", "query": "#1\nClinical Scenario:\nA 56-year-old man with end-stage liver disease secondary to NASH cirrhosis is undergoing orthotopic liver transplantation. Thirty minutes after reperfusion, the surgical team notes ongoing oozing from the anastomotic site. ROTEM is performed and shows:\n\t\u2022\tEXTEM A10: 35 mm \n\t\u2022\tEXTEM CFT: 145 s \n\t\u2022\tFIBTEM A10: 7 mm \n\t\u2022\tEXTEM CT: 80 s\n\t\u2022\tML EXTEM: 5%\n\nClinical Question:\nWhat is the next best step in therapy? Give a precise, single best answer.\n", "answer_length": 122, "response_time_seconds": 2.244846}
{"timestamp": "2025-05-26 12:12:52.912614", "session_id": "883b99b3", "query": "#2\nCoagulation Factor Deficiency Case\n\nClinical Scenario:\nA 62-year-old female undergoing liver transplant for hepatitis C cirrhosis has ROTEM results 15 minutes into the anhepatic phase showing:\n\t\u2022\tEXTEM CT: 145 s \n\t\u2022\tEXTEM CFT: 120 s\n\t\u2022\tEXTEM A10: 39 mm \n\t\u2022\tFIBTEM A10: 13 mm\n\t\u2022\tML EXTEM: 4%\n", "answer_length": 30, "response_time_seconds": 3.806785}
{"timestamp": "2025-05-26 12:13:59.401455", "session_id": "883b99b3", "query": "#2\nCoagulation Factor Deficiency Case\n\nClinical Scenario:\nA 62-year-old female undergoing liver transplant for hepatitis C cirrhosis has ROTEM results 15 minutes into the anhepatic phase showing:\n\t\u2022\tEXTEM CT: 145 s \n\t\u2022\tEXTEM CFT: 120 s\n\t\u2022\tEXTEM A10: 39 mm \n\t\u2022\tFIBTEM A10: 13 mm\n\t\u2022\tML EXTEM: 4%\n\nGive a single precise answer with a brief explanation of your rationale", "answer_length": 144, "response_time_seconds": 4.211074}
{"timestamp": "2025-05-26 12:14:25.279759", "session_id": "883b99b3", "query": "#2 Coagulation Factor Deficiency Case\n\nClinical Scenario: A 62-year-old female undergoing liver transplant for hepatitis C cirrhosis has ROTEM results 15 minutes into the anhepatic phase showing: \u2022 EXTEM CT: 145 s \u2022 EXTEM CFT: 120 s \u2022 EXTEM A10: 39 mm \u2022 FIBTEM A10: 13 mm \u2022 ML EXTEM: 4%", "answer_length": 392, "response_time_seconds": 4.328199}
{"timestamp": "2025-05-26 12:15:07.334978", "session_id": "883b99b3", "query": "Clinical Scenario:\nA 62-year-old female undergoing liver transplant for hepatitis C cirrhosis has ROTEM results 15 minutes into the anhepatic phase showing:\n\t\u2022\tEXTEM CT: 145 s \n\t\u2022\tEXTEM CFT: 120 s\n\t\u2022\tEXTEM A10: 39 mm \n\t\u2022\tFIBTEM A10: 13 mm\n\t\u2022\tML EXTEM: 4%\n\nClinical Question:\nWhat is the next best step in therapy? Give a precise, single best answer.\n", "answer_length": 408, "response_time_seconds": 3.932571}
{"timestamp": "2025-05-26 12:15:25.533205", "session_id": "883b99b3", "query": "Clinical Scenario:\nA 62-year-old female undergoing liver transplant for hepatitis C cirrhosis has ROTEM results 15 minutes into the anhepatic phase showing:\n\t\u2022\tEXTEM CT: 145 s \n\t\u2022\tEXTEM CFT: 120 s\n\t\u2022\tEXTEM A10: 39 mm \n\t\u2022\tFIBTEM A10: 13 mm\n\t\u2022\tML EXTEM: 4%\n\nClinical Question:\nWhat is the next best step in therapy? Give a precise, single best answer.\n\ngive an explanation", "answer_length": 565, "response_time_seconds": 5.331506}
{"timestamp": "2025-05-26 15:28:09.410430", "session_id": "e1a0f3c9", "query": "Clinical Scenario:\nA 62-year-old female undergoing liver transplant for hepatitis C cirrhosis has ROTEM results 15 minutes into the anhepatic phase showing:\n\t\u2022\tEXTEM CT: 145 s \n\t\u2022\tEXTEM CFT: 120 s\n\t\u2022\tEXTEM A10: 39 mm \n\t\u2022\tFIBTEM A10: 13 mm\n\t\u2022\tML EXTEM: 4%\n\nClinical Question:\nWhat is the next best step in therapy? Give a precise, single best answer.\n", "answer_length": 30, "response_time_seconds": 2.374708}
{"timestamp": "2025-05-26 15:43:19.881805", "session_id": "e1a0f3c9", "query": "Clinical Scenario: A 62-year-old female undergoing liver transplant for hepatitis C cirrhosis has ROTEM results 15 minutes into the anhepatic phase showing: \u2022 EXTEM CT: 145 s \u2022 EXTEM CFT: 120 s \u2022 EXTEM A10: 39 mm \u2022 FIBTEM A10: 13 mm \u2022 ML EXTEM: 4%\n\nClinical Question: What is the next best step in therapy? Give a precise, single best answer.\n\n", "answer_length": 28, "response_time_seconds": 3.831884}
{"timestamp": "2025-05-26 15:51:47.878868", "session_id": "e1a0f3c9", "query": "Clinical Scenario: A 62-year-old female undergoing liver transplant for hepatitis C cirrhosis has ROTEM results 15 minutes into the anhepatic phase showing: \u2022 EXTEM CT: 145 s \u2022 EXTEM CFT: 120 s \u2022 EXTEM A10: 39 mm \u2022 FIBTEM A10: 13 mm \u2022 ML EXTEM: 4%\n\nClinical Question: What is the next best step in therapy? Give a precise, single best answer", "answer_length": 28, "response_time_seconds": 2.289582}
{"timestamp": "2025-05-26 17:28:02.809582", "session_id": "82f046dc", "query": "#1\nClinical Scenario:\nA 56-year-old man with end-stage liver disease secondary to NASH cirrhosis is undergoing orthotopic liver transplantation. Thirty minutes after reperfusion, the surgical team notes ongoing oozing from the anastomotic site. ROTEM is performed and shows:\n\t\u2022\tEXTEM A10: 35 mm \n\t\u2022\tEXTEM CFT: 145 s \n\t\u2022\tFIBTEM A10: 7 mm \n\t\u2022\tEXTEM CT: 80 s\n\t\u2022\tML EXTEM: 5%\n\nClinical Question:\nWhat is the next best step in therapy? Give a precise, single best answer.\n", "answer_length": 122, "response_time_seconds": 3.429092}
{"timestamp": "2025-05-26 17:32:48.470877", "session_id": "82f046dc", "query": "#1 Clinical Scenario: A 56-year-old man with end-stage liver disease secondary to NASH cirrhosis is undergoing orthotopic liver transplantation. Thirty minutes after reperfusion, the surgical team notes ongoing oozing from the anastomotic site. ROTEM is performed and shows: \u2022 EXTEM A10: 35 mm \u2022 EXTEM CFT: 145 s \u2022 FIBTEM A10: 7 mm \u2022 EXTEM CT: 80 s \u2022 ML EXTEM: 5%\n\nClinical Question: What is the next best step in therapy? Give a precise, single best answer.", "answer_length": 125, "response_time_seconds": 4.226981}
{"timestamp": "2025-05-26 17:36:28.122351", "session_id": "fcc60e9c", "query": "#1\nClinical Scenario:\nA 56-year-old man with end-stage liver disease secondary to NASH cirrhosis is undergoing orthotopic liver transplantation. Thirty minutes after reperfusion, the surgical team notes ongoing oozing from the anastomotic site. ROTEM is performed and shows:\n\t\u2022\tEXTEM A10: 35 mm \n\t\u2022\tEXTEM CFT: 145 s \n\t\u2022\tFIBTEM A10: 7 mm \n\t\u2022\tEXTEM CT: 80 s\n\t\u2022\tML EXTEM: 5%\n\nClinical Question:\nWhat is the next best step in therapy? Give a precise, single best answer.\n", "answer_length": 122, "response_time_seconds": 2.371034}
{"timestamp": "2025-05-26 17:40:47.496649", "session_id": "fcc60e9c", "query": "#1 Clinical Scenario: A 56-year-old man with end-stage liver disease secondary to NASH cirrhosis is undergoing orthotopic liver transplantation. Thirty minutes after reperfusion, the surgical team notes ongoing oozing from the anastomotic site. ROTEM is performed and shows: \u2022 EXTEM A10: 35 mm \u2022 EXTEM CFT: 145 s \u2022 FIBTEM A10: 7 mm \u2022 EXTEM CT: 80 s \u2022 ML EXTEM: 5%\n\nClinical Question: What is the next best step in therapy? Give a precise, single best answer.", "answer_length": 174, "response_time_seconds": 2.892182}
{"timestamp": "2025-05-26 17:44:04.136487", "session_id": "fcc60e9c", "query": "#1 Clinical Scenario: A 56-year-old man with end-stage liver disease secondary to NASH cirrhosis is undergoing orthotopic liver transplantation. Thirty minutes after reperfusion, the surgical team notes ongoing oozing from the anastomotic site. ROTEM is performed and shows: \u2022 EXTEM A10: 35 mm \u2022 EXTEM CFT: 145 s \u2022 FIBTEM A10: 7 mm \u2022 EXTEM CT: 80 s \u2022 ML EXTEM: 5%\n\nClinical Question: What is the next best step in therapy? Give a precise, single best answer.", "answer_length": 265, "response_time_seconds": 4.595504}
{"timestamp": "2025-05-26 18:24:26.022927", "session_id": "57de0efb", "query": "#1\nClinical Scenario:\nA 56-year-old man with end-stage liver disease secondary to NASH cirrhosis is undergoing orthotopic liver transplantation. Thirty minutes after reperfusion, the surgical team notes ongoing oozing from the anastomotic site. ROTEM is performed and shows:\n\t\u2022\tEXTEM A10: 35 mm \n\t\u2022\tEXTEM CFT: 145 s \n\t\u2022\tFIBTEM A10: 7 mm \n\t\u2022\tEXTEM CT: 80 s\n\t\u2022\tML EXTEM: 5%\n\nClinical Question:\nWhat is the next best step in therapy? Give a precise, single best answer.\n", "answer_length": 122, "response_time_seconds": 2.238977}
{"timestamp": "2025-05-26 18:29:57.633648", "session_id": "57de0efb", "query": "#1 Clinical Scenario: A 56-year-old man with end-stage liver disease secondary to NASH cirrhosis is undergoing orthotopic liver transplantation. Thirty minutes after reperfusion, the surgical team notes ongoing oozing from the anastomotic site. ROTEM is performed and shows: \u2022 EXTEM A10: 35 mm \u2022 EXTEM CFT: 145 s \u2022 FIBTEM A10: 7 mm \u2022 EXTEM CT: 80 s \u2022 ML EXTEM: 5%\n\nClinical Question: What is the next best step in therapy? Give a precise, single best answer.", "answer_length": 124, "response_time_seconds": 4.799893}
{"timestamp": "2025-05-26 18:34:22.230389", "session_id": "57de0efb", "query": "#1\nClinical Scenario:\nA 56-year-old man with end-stage liver disease secondary to NASH cirrhosis is undergoing orthotopic liver transplantation. Thirty minutes after reperfusion, the surgical team notes ongoing oozing from the anastomotic site. ROTEM is performed and shows:\n\t\u2022\tEXTEM A10: 35 mm \n\t\u2022\tEXTEM CFT: 145 s \n\t\u2022\tFIBTEM A10: 7 mm \n\t\u2022\tEXTEM CT: 80 s\n\t\u2022\tML EXTEM: 5%\n\nClinical Question:\nWhat is the next best step in therapy? Give a precise, single best answer.", "answer_length": 23, "response_time_seconds": 2.705228}
{"timestamp": "2025-05-26 18:39:22.573487", "session_id": "57de0efb", "query": "#1 Clinical Scenario: A 56-year-old man with end-stage liver disease secondary to NASH cirrhosis is undergoing orthotopic liver transplantation. Thirty minutes after reperfusion, the surgical team notes ongoing oozing from the anastomotic site. ROTEM is performed and shows: \u2022 EXTEM A10: 35 mm \u2022 EXTEM CFT: 145 s \u2022 FIBTEM A10: 7 mm \u2022 EXTEM CT: 80 s \u2022 ML EXTEM: 5%\n\nClinical Question: What is the next best step in therapy? Give a precise, single best answer.", "answer_length": 74, "response_time_seconds": 4.316753}
{"timestamp": "2025-05-27 10:09:34.504606", "session_id": "f7199e48", "query": "#1 Clinical Scenario: A 56-year-old man with end-stage liver disease secondary to NASH cirrhosis is undergoing orthotopic liver transplantation. Thirty minutes after reperfusion, the surgical team notes ongoing oozing from the anastomotic site. ROTEM is performed and shows: \u2022 EXTEM A10: 35 mm \u2022 EXTEM CFT: 145 s \u2022 FIBTEM A10: 7 mm \u2022 EXTEM CT: 80 s \u2022 ML EXTEM: 5%\n\nClinical Question: What is the next best step in therapy? Explain why?", "answer_length": 563, "response_time_seconds": 3.955861}
{"timestamp": "2025-05-27 10:10:04.725035", "session_id": "f7199e48", "query": "#1 Clinical Scenario: A 56-year-old man with end-stage liver disease secondary to NASH cirrhosis is undergoing orthotopic liver transplantation. Thirty minutes after reperfusion, the surgical team notes ongoing oozing from the anastomotic site. ROTEM is performed and shows: \u2022 EXTEM A10: 35 mm \u2022 EXTEM CFT: 145 s \u2022 FIBTEM A10: 7 mm \u2022 EXTEM CT: 80 s \u2022 ML EXTEM: 5%\n\nClinical Question: What is the next best step in therapy? ", "answer_length": 364, "response_time_seconds": 2.344342}
{"timestamp": "2025-06-04 22:31:40.928003", "session_id": "e4ccbd19", "query": "A 56-year-old man with end-stage liver disease secondary to NASH cirrhosis is undergoing orthotopic liver transplantation. Thirty minutes after reperfusion, the surgical team notes ongoing oozing from the anastomotic site. ROTEM is performed and shows:\n\t\u2022\tEXTEM A10: 35 mm \n\t\u2022\tEXTEM CFT: 145 s \n\t\u2022\tFIBTEM A10: 7 mm \n\t\u2022\tEXTEM CT: 80 s\n\t\u2022\tML EXTEM: 5%\n\nClinical Question:\nWhat is the next best step in therapy? Give a precise, single best answer.\n", "answer_length": 23, "response_time_seconds": 2.211282}
{"timestamp": "2025-06-04 22:38:32.835273", "session_id": "e4ccbd19", "query": "A 56-year-old man with end-stage liver disease secondary to NASH cirrhosis is undergoing orthotopic liver transplantation. Thirty minutes after reperfusion, the surgical team notes ongoing oozing from the anastomotic site. ROTEM is performed and shows: \u2022 EXTEM A10: 35 mm \u2022 EXTEM CFT: 145 s \u2022 FIBTEM A10: 7 mm \u2022 EXTEM CT: 80 s \u2022 ML EXTEM: 5%\n\nClinical Question: What is the next best step in therapy? Give a precise, single best answer.\n\nexplain your reasoning", "answer_length": 23, "response_time_seconds": 4.56987}
{"timestamp": "2025-06-04 22:39:04.120774", "session_id": "e4ccbd19", "query": "A 56-year-old man with end-stage liver disease secondary to NASH cirrhosis is undergoing orthotopic liver transplantation. Thirty minutes after reperfusion, the surgical team notes ongoing oozing from the anastomotic site. ROTEM is performed and shows: \u2022 EXTEM A10: 35 mm \u2022 EXTEM CFT: 145 s \u2022 FIBTEM A10: 7 mm \u2022 EXTEM CT: 80 s \u2022 ML EXTEM: 5%\n\nClinical Question: What is the next best step in therapy? explain your reasoning", "answer_length": 984, "response_time_seconds": 4.913961}
{"timestamp": "2025-06-04 22:39:19.606697", "session_id": "e4ccbd19", "query": "Are you using RAG", "answer_length": 307, "response_time_seconds": 2.715878}
